Preexisting Psychiatric Treatment During Stimulant Care in CO

Preexisting psychiatric treatment during stimulant care does not require an automatic reset. The ASAM/AAAP guideline recommends reviewing the established plan, ideally with existing providers, and continuing current medicines when appropriate after considering safety. Starting treatment for stimulant use does not, by itself, mean psychiatric care should be discarded. See Recommendation 25.

If psychiatric treatment has helped you, the thought of losing it may make seeking stimulant-use care feel risky. You may value a familiar clinician, a medicine, or goals you have worked toward for years. Those parts of your care deserve consideration. At the same time, a new treatment need can change what is appropriate now. The aim is to preserve useful care while reviewing its safety and fit, rather than promise that every prescription or outside arrangement will stay unchanged. Recommendation 25 addresses this balance for people entering stimulant-use-disorder treatment with an established psychiatric diagnosis.

Does starting stimulant treatment require resetting psychiatric care?

No. Starting stimulant treatment calls for a review of existing psychiatric care, not its automatic replacement. The broader approach to mental-health care when substance use is also a concern keeps both needs in view. Women’s Recovery’s outpatient treatment programs provide a setting for discussing those needs, without guaranteeing a particular medication decision.

Recommendation 25 of the American Society of Addiction Medicine and American Academy of Addiction Psychiatry guideline has two linked parts: review the existing plan, ideally in coordination with established providers, and continue current medicines as appropriate. Safety must be considered in the context of possible continued stimulant use and use of other substances. The recommendation states these responsibilities together.

That wording matters if you fear that being honest about stimulant use will make everything about earlier care irrelevant. Seeking help adds a treatment need. It does not automatically erase the purpose of psychiatric treatment or the benefit you have experienced from it.

The recommendation is a strong recommendation based on clinical consensus. Its supporting discussion acknowledges a lack of direct evidence for this specific decision. It supports preserving appropriate psychiatric treatment while stimulant treatment is integrated, rather than routinely discontinuing psychiatric care. This is clinical guidance, not a guarantee that any particular medicine will remain suitable. See the discussion preceding Recommendation 25.

What does reviewing an established treatment plan mean?

Review means examining what the plan is meant to do and whether it remains appropriate in the current situation. It is broader than choosing a prescription. The relationship between psychiatric support and outpatient treatment illustrates that wider role, while care for ADHD alongside stimulant use disorder addresses one condition-specific example.

An established plan may include medication, therapy, and goals for daily functioning. Reviewing it allows clinicians to consider those parts together instead of treating a medication name as the whole story. Under Recommendation 25, the review should inform continuation, with attention to present safety.

The following distinctions explain why neither automatic continuation nor automatic discontinuation captures the guideline’s approach.

A useful review can connect several parts of the established plan:

• Treatment purpose: the psychiatric concern each part of care is intended to address.
• Experience of benefit: what has helped and which needs remain unresolved.
• Current safety: how prescribed treatment fits with possible stimulant and other substance use.
• The combined plan: how psychiatric treatment and stimulant-focused care can work during the same period.

These are clinical review topics, not a list you must complete before contacting care. A review can result in appropriate treatment continuing. It can also identify a reason for clinician-directed change without making all earlier treatment worthless.

Why does appropriate continuation differ from unchanged prescribing?

Appropriate continuation means a clinician judges that treatment still fits after considering relevant risks. It does not promise that every prescription remains identical. The distinction between medication considered for stimulant use disorder and psychiatric medication also matters, especially when several substances are involved in care.

Recommendation 25 explicitly includes the possibility that stimulant or other substance use may continue. Medication safety should therefore reflect the person’s actual circumstances, rather than depend on an assumption that all substance use has ended. This is a reason for individualized review, not a statement that combining substances with prescribed medication is safe. See Recommendation 25 and the guideline’s co-occurring-disorders guidance.

A psychiatric medicine can have a valid purpose without treating stimulant use disorder itself. For example, continuing appropriate care for an established psychiatric condition does not establish that stimulant-use patterns have been addressed. The reverse is also true: beginning stimulant-focused behavioral treatment does not establish that an existing psychiatric medicine is no longer needed.

The guideline’s phrase “as appropriate” leaves room for clinical judgment. It does not give a reader a rule for selecting which medicines to keep. Feeling helped by a prescription is relevant, but it cannot settle every safety question. Concern about a prescription also deserves attention without becoming a reason to change it alone.

How can psychiatric treatment and stimulant-focused therapy keep different jobs?

Both can remain active because they address related but distinct treatment needs. Cognitive behavioral therapy for stimulant use focuses on patterns linked to substance use, while contingency management reinforces defined treatment behaviors. Neither automatically replaces established psychiatric treatment.

The ASAM/AAAP guideline recommends treating stimulant use disorder and co-occurring disorders concurrently, meaning during the same period of care. It recommends an integrated behavioral approach when available. Otherwise, stimulant-focused behavioral treatment should be tailored to consider interactions between the conditions. Recommendations 21 and 22 describe this approach.

The jobs within a combined plan can remain clear:

• Established psychiatric treatment addresses the condition for which that care was developed, with current appropriateness reviewed.
• Stimulant-focused behavioral treatment addresses substance-use patterns and responses to situations linked with use.
• Integrated clinical planning considers how psychiatric needs and stimulant use affect each other.
• Medication safety review considers the established prescription in the context of possible continued substance use.

For example, work on recognizing situations linked with stimulant use has a different target from medication prescribed for a preexisting psychiatric condition. Both targets can matter in one week. Progress on one does not prove the other has been resolved. NIDA describes behavioral therapies as ways to change drug-related attitudes and behaviors and cope with stressful situations and triggers. It also states that treatment should address mental-health, medical, and social needs alongside drug use. See NIDA’s treatment and recovery principles.

Concurrent care does not mean one professional must provide everything or that every treatment method will be offered by one program. It means the plan should account for both concerns rather than require one to disappear before the other deserves care. Educational descriptions of treatment methods do not establish their availability at Women’s Recovery.

What role can an established psychiatric provider have?

An established provider can contribute to reviewing the plan when coordination is appropriate. Women’s Recovery’s Intensive Outpatient Program (IOP) and Partial Hospitalization Program (PHP) describe outside-provider involvement as dependent on client consent and the care plan. They do not promise that every outside arrangement will remain unchanged.

Recommendation 25 says review should ideally occur in coordination with existing treatment providers. The established clinician’s knowledge can help explain the plan’s purpose and treatment history. That contribution is relevant even when stimulant-use treatment brings new safety considerations into the discussion. See the existing-provider provision in Recommendation 25.

The purpose is a better-informed decision, rather than automatic deference to either the old plan or the newest clinician. Earlier treatment experience remains meaningful. Current substance-use risks remain meaningful too. Coordination should help clinicians consider both, without making you choose which part of your health deserves attention.

Your perspective also belongs in that decision. You may value a treatment because of changes you have noticed in daily life, or have concerns about how it feels. The guideline states that patients should receive information about risks, benefits, and alternatives and be active participants in shared decision-making whenever feasible. See the guideline’s patient decision-making guidance.

This does not settle which clinician will provide each part of care. It establishes why existing treatment knowledge and your experience should inform the plan, rather than be ignored simply because a new treatment need has emerged.

Why should seeking help not depend on stopping psychiatric treatment yourself?

You should not have to perform a self-directed psychiatric-treatment reset before seeking help. Women’s Recovery’s outpatient programs can be explored while current treatment remains part of the clinical discussion. You can contact the team without first deciding which psychiatric treatment should stay or change.

The guideline assigns treatment review and appropriate medication continuation to clinicians. It does not make stopping prescribed psychiatric care a patient task. A loved one can respect that boundary by supporting access to professional care rather than setting medication changes as a condition of help. Recommendation 25 supports clinician-led review.

Preserving appropriate treatment is different from ignoring urgent symptoms. Call 911 immediately for suspected overdose, chest pain, a seizure, dangerous overheating, or severe or escalating agitation or psychosis after stimulant use. The guideline identifies potentially life-threatening stimulant complications that require acute care. For suicidal thoughts or a mental-health crisis, call or text 988, as listed in NIMH’s crisis guidance; immediate danger requires 911. See the acute-care and psychiatric-safety recommendations. Routine admissions contact is not emergency care.

Women’s Recovery provides outpatient mental-health, trauma, and substance-use programs in Denver, CO, including PHP and IOP. It does not provide onsite detox, residential, or inpatient services. Its program descriptions do not confirm any specific stimulant-use medication or guarantee continuation of an outside prescription.

To explore current outpatient options, call 833.754.0554. The starting point is consideration of your established care alongside the new treatment need, with clinical review rather than an automatic reset.

Frequently asked questions